title: Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
abstract: OBJECTIVE
  Zoledronic acid (ZA) reduces the risk of skeletal-related events (SREs) in castration-resistant prostate cancer (CRPC) with bone metastasis and improves quality of life. It remains unclear when clinicians should initiate ZA treatment.
  
  
  METHODS
  Hormone-naïve patients were randomized to a combined androgen blockade (CAB) group or CAB with ZA group (CAB-ZA) based on Gleason score (GS) or extent of disease. The primary end-point of the study was progression-free survival (PFS) and the secondary end-point was incidence of SREs and bone pain.
  
  
  RESULTS
  Thirty-one and 29 patients among 60 enrolled patients were assigned to the CAB group and the CAB-ZA group, respectively. There was no significant difference in PFS between the two groups. Subgroup analyses revealed better PFS in the CAB-ZA group with GS ≥8 (p=0.021). Moreover, incidence of SREs, including bone pain, was lower in the CAB-ZA group (p=0.019).
  
  
  CONCLUSIONS
  CAB-ZA treatment was found to improve PFS for patients with prostate cancer with high GS. CAB-ZA treatment could be recommended for treatment of patients with prostate cancer.
authors.affiliation: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8640, Japan. mizokami@med.kanazawa-u.ac.jp.
authors.forename: Satoru
authors.initials: S
authors.lastname: Ueno
authors.forename: Atsushi
authors.initials: A
authors.lastname: Mizokami
authors.forename: Takashi
authors.initials: T
authors.lastname: Fukagai
authors.forename: Naohiro
authors.initials: N
authors.lastname: Fujimoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Oh-Oka
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Kondo
authors.forename: Gaku
authors.initials: G
authors.lastname: Arai
authors.forename: Hisamitsu
authors.initials: H
authors.lastname: Ide
authors.forename: Shigeo
authors.initials: S
authors.lastname: Horie
authors.forename: Osamu
authors.initials: O
authors.lastname: Ueki
authors.forename: Kouhei
authors.initials: K
authors.lastname: Kawaguchi
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Shimamura
authors.forename: Matsuo
authors.initials: M
authors.lastname: Orito
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Ishida
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ikeda
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077211:Zoledronic Acid
chemical_list: D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid
keywords: Prostate cancer; bone metastasis; combined androgen blockade; zoledronic acid